Lixte Biotechnology Holdings is a California-based drug discovery company using biomarker tech to identify enzyme targets involved in common diseases and designing novel compounds to tackle them. The company develops two series of pharmacologically active drugs for the treatment of cancers, vascular and metabolic diseases, and chronic hereditary diseases such as Gaucher's disease and neurodegenerative diseases; and collaborates with the Moffitt Cancer Center, Research Institute Hospital Inc., the Spanish Sarcoma Group, Netherlands Cancer Institute, and Oncode Institute. Lixte Biotechnology Holdings has been operational since 2005.